Veenhuis Rob T, van Horssen Jack, Bos Rob P, Anzion Rob B M, Van Der Valk Pieter G M
Department of Dermatology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Arch Dermatol Res. 2002 Jul;294(4):168-71. doi: 10.1007/s00403-002-0311-5. Epub 2002 Jun 4.
Coal tar preparations, as used in dermatological practice, contain numerous polycyclic aromatic hydrocarbons of which many are proven animal carcinogens. Increased urinary 1-hydroxypyrene excretion in patients with atopic dermatitis treated with topical coal tar preparations has been demonstrated. Little is known about the relationship between the dermal uptake of polycyclic aromatic hydrocarbons on the one hand and the amount of tar applied to the skin, the total body area affected, the condition of the epidermal barrier and the severity of the dermatitis on the other. We compared urinary 1-hydroxypyrene excretion rate with these variables. The urinary 1-hydroxypyrene excretion rate was highly dependent on the total amount of tar applied to the skin and the total body area affected, and less on the severity of the atopic dermatitis or the condition of the epidermal barrier. Exposure to therapeutic doses of coal tar leads to much higher rates of urinary 1-hydroxypyrene excretion than occupational exposure. Because of the potential carcinogenicity of coal tar, as clearly demonstrated both in animal studies and from occupational exposure, careful consideration should be given to the use of coal tar preparations in dermatological practice. However, the risk of short-term high exposure is unknown. Restriction of the use of coal tar should be based on epidemiological studies and/or appropriate risk models taking into account its relative safety established over many years of clinical use.
在皮肤科实践中使用的煤焦油制剂含有多种多环芳烃,其中许多已被证实是动物致癌物。已证明外用煤焦油制剂治疗的特应性皮炎患者尿中1-羟基芘排泄增加。一方面,多环芳烃的皮肤吸收与另一方面涂抹于皮肤的煤焦油剂量、受累的全身面积、表皮屏障状况以及皮炎严重程度之间的关系鲜为人知。我们将尿中1-羟基芘排泄率与这些变量进行了比较。尿中1-羟基芘排泄率高度依赖于涂抹于皮肤的煤焦油总量和受累的全身面积,而较少依赖于特应性皮炎的严重程度或表皮屏障状况。与职业暴露相比,接触治疗剂量的煤焦油会导致尿中1-羟基芘排泄率高得多。鉴于动物研究和职业暴露均清楚表明煤焦油具有潜在致癌性,在皮肤科实践中使用煤焦油制剂时应谨慎考虑。然而,短期高暴露的风险尚不清楚。煤焦油使用的限制应基于流行病学研究和/或适当的风险模型,并考虑到其在多年临床使用中确立的相对安全性。